Short Interest in Pharma Mar (OTCMKTS:PHMMF) Declines By 52.8%

Pharma Mar (OTCMKTS:PHMMF) was the target of a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 94 shares, a decline of 52.8% from the July 30th total of 199 shares. Based on an average trading volume of 27 shares, the days-to-cover ratio is presently 3.5 days. Approximately 0.0% of the company’s shares are sold short.

Pharma Mar Stock Performance

Pharma Mar stock traded down $2.76 during mid-day trading on Monday, hitting $94.60. The company’s stock had a trading volume of 100 shares, compared to its average volume of 1,893. Pharma Mar has a 52-week low of $77.41 and a 52-week high of $110.40. The company has a quick ratio of 2.44, a current ratio of 3.02 and a debt-to-equity ratio of 0.14. The firm’s 50 day moving average is $85.95 and its 200 day moving average is $93.57.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Chardan Capital raised shares of Pharma Mar to a “strong-buy” rating in a research note on Tuesday, June 9th. Zacks Research raised shares of Pharma Mar to a “hold” rating in a research note on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Pharma Mar currently has a consensus rating of “Buy”.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.